Corient Private Wealth LP bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 23,797 shares of the biopharmaceutical company’s stock, valued at approximately $7,163,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ALNY. Daiwa Securities Group Inc. grew its holdings in Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after acquiring an additional 35 shares during the last quarter. Golden State Wealth Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the period. Coldstream Capital Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 2.4% in the third quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $748,000 after purchasing an additional 38 shares during the last quarter. Atlantic Union Bankshares Corp increased its holdings in Alnylam Pharmaceuticals by 20.9% during the 4th quarter. Atlantic Union Bankshares Corp now owns 231 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 40 shares during the period. Finally, Laird Norton Wetherby Wealth Management LLC raised its position in Alnylam Pharmaceuticals by 3.3% during the 3rd quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,266 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 40 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on ALNY. Wells Fargo & Company cut their price objective on Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating on the stock in a research report on Friday, August 14th. BMO Capital Markets initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 19th. They set an “outperform” rating and a $318.00 price target on the stock. Oppenheimer decreased their price target on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Stifel Nicolaus lowered their price objective on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a report on Friday, July 31st. Finally, HC Wainwright cut their price objective on Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $386.14.
Alnylam Pharmaceuticals Stock Performance
Shares of Alnylam Pharmaceuticals stock opened at $237.10 on Monday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $197.81 and a 12 month high of $495.55. The firm has a market capitalization of $31.73 billion, a P/E ratio of 44.07 and a beta of 0.30. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The business has a fifty day simple moving average of $262.62 and a two-hundred day simple moving average of $293.54.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. The firm had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company’s revenue was up 66.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.51) EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Further Reading
- Five stocks we like better than Alnylam Pharmaceuticals
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
